Capricor Therapeutics (CAPR) Equity Average (2011 - 2026)

Capricor Therapeutics' Equity Average history runs 16 years deep, the most recent figure standing at $292.2 million for Q1 2026.

• In Q1 2026, Equity Average rose 114.02% year-over-year to $292.2 million; the TTM figure through Mar 2026 stood at $292.2 million (up 114.02% YoY), while the FY2025 annual figure was $225.6 million, up 168.5% from the prior year.
• Equity Average was $292.2 million for Q1 2026 at Capricor Therapeutics, up from $194.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $292.2 million in Q1 2026 to a low of $471753.5 in Q3 2023.
• Historically, Equity Average has averaged $66.0 million across 5 years, with a median of $21.7 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Equity Average tumbled 97.24% in 2023, then surged 8354.34% in 2024.
• A 5-year view of Equity Average shows it stood at $13.6 million in 2022, then slipped by 23.51% to $10.4 million in 2023, then jumped by 926.85% to $106.9 million in 2024, then surged by 82.32% to $194.8 million in 2025, then jumped by 50.0% to $292.2 million in 2026.
• The last three Equity Average figures came in at $292.2 million (Q1 2026), $194.8 million (Q4 2025), and $94.4 million (Q3 2025), per Business Quant data.